DOI . ORG {
}
We began analyzing https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT, but it redirected us to https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT. The analysis below is for the second page.
Title[redir]:
Clinical applications of PD-1-based therapy: a focus on pembrolizumab | OTT
Description:
Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types Tara C Gangadhar,1 April KS Salama2 1Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA; 2Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA Abstract: Preclinical work has led to an increased understanding of the immunomodulatory mechanisms involved in the regulation of the antitumor response in a variety of tumor types. PD-1 (programmed death 1) appears to be a key checkpoint involved in immune suppression in the tumor microenvironment, even in diseases not previously thought to be sensitive to immune manipulation. More recently, the subsequent clinical development of PD-1-based therapy has resulted in a major breakthrough in the field of oncology. Pembrolizumab, a humanized highly selective IgG4 anti-PD-1 monoclonal antibody, was recently approved for the treatment of advanced melanoma based on promising early-phase clinical data. Encouraging results have also been seen in other malignancies, and PD-1-targeted therapies are likely to markedly change the treatment landscape. Future work will center on rationally designed combination strategies in order to potentiate the antitumor immune response and overcome mechanisms of resistance. Keywords: PD-1, cancer, pembrolizumab, nivolumab, immunotherapy, antitumor activity
Title[redir]:
Clinical applications of PD-1-based therapy: a focus on pembrolizumab | OTT
Description:
Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types Tara C Gangadhar,1 April KS Salama2 1Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA; 2Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA Abstract: Preclinical work has led to an increased understanding of the immunomodulatory mechanisms involved in the regulation of the antitumor response in a variety of tumor types. PD-1 (programmed death 1) appears to be a key checkpoint involved in immune suppression in the tumor microenvironment, even in diseases not previously thought to be sensitive to immune manipulation. More recently, the subsequent clinical development of PD-1-based therapy has resulted in a major breakthrough in the field of oncology. Pembrolizumab, a humanized highly selective IgG4 anti-PD-1 monoclonal antibody, was recently approved for the treatment of advanced melanoma based on promising early-phase clinical data. Encouraging results have also been seen in other malignancies, and PD-1-targeted therapies are likely to markedly change the treatment landscape. Future work will center on rationally designed combination strategies in order to potentiate the antitumor immune response and overcome mechanisms of resistance. Keywords: PD-1, cancer, pembrolizumab, nivolumab, immunotherapy, antitumor activity
Matching Content Categories {📚}
- Science
- Health & Fitness
- Education
Content Management System {📝}
What CMS is doi.org built with?
Custom-built
No common CMS systems were detected on Doi.org, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of doi.org audience?
🌟 Strong Traffic: 100k - 200k visitors per month
Based on our best estimate, this website will receive around 100,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Doi.org Make Money? {💸}
We don’t know how the website earns money.
Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Doi.org could be getting rich in stealth mode, or the way it's monetizing isn't detectable.
Keywords {🔍}
patients, cancer, pembrolizumab, melanoma, pdl, cell, response, clinical, advanced, tumor, therapy, immune, expression, study, activity, clin, lung, cells, treated, treatment, weeks, mgkg, phase, oncol, ipilimumab, tumors, antibody, survival, responses, nsclc, med, including, nivolumab, combination, carcinoma, tcell, safety, randomized, potential, renal, trial, metastatic, rates, disease, compared, medical, programmed, death, antipd, results,
Topics {✒️}
single-agent anti-programmed death-1 anti-programmed-death-receptor-1 treatment duke university medical center inhibit t-cell activation steady-state concentrations reached high-dose recombinant interleukin-2 castration-resistant prostate cancer anti-pd-1 antibody prevents provoked t-cell dysfunction egfr-targeted antibody cetuximab dysfunctional t-cell phenotype t-cell effector functions b7-h1+ lymphocyte clusters castrate-resistant prostate cancer humanized pd-1-blocking antibody global health status/quality dove medical press anti-pd-l1 antibody restore t-cell function including fast-track processing derive long-term benefits treatment-related adverse events pd-1-directed therapy makes small-cell lung cancer dose-proportional pharmacokinetic parameters manuscript login pd-1-based therapy represents anti-ctla-4 antibody ipilimumab immune-related response criteria effective single-agent long-term survival update advanced egfr mutation-positive long-term disease control preliminary progression-free survival braf v600-mutant melanoma tumor-infiltrating immune cells pd-1-positive intraepithelial lymphocytes abramson cancer center advanced human cancer–response humanized antibody interacting favored authors including antiangiogenic-based therapies tumors express pd-l1 pd-l1-based approaches long elimination half-life pd-l1 tumor expression anti-pd-1 antibody t-cell activation squamous cell carcinoma specific author
Questions {❓}
- Why publish with us?
Social Networks {👍}(9)
- https://www.facebook.com/DoveMedicalPress
- https://twitter.com/DovePress
- https://www.linkedin.com/company/dove-medical-press
- https://www.youtube.com/user/dovepress
- https://www.instagram.com/dovemedicalpress/
- https://twitter.com/intent/tweet?text=Clinical+applications+of+PD-1-based+therapy%3A+a+focus+on+pembrolizumab++%7C+OTT+%40DovePress&related=DovePress&url=https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT
- https://www.facebook.com/sharer.php?u=https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT&t=Clinical applications of PD-1-based therapy: a focus on pembrolizumab | OTT
- https://www.linkedin.com/shareArticle?mini=true&url=https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT&title=Clinical applications of PD-1-based therapy: a focus on pembrolizumab | OTT&source=Dove Press
- https://www.reddit.com/submit?url=https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT
External Links {🔗}(180)
- What are the total earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/browse_journals.php?
- Earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/about-us
- What are the total earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/editorial-policies?
- What's the monthly money flow for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/author-guidelines?
- How much profit does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/peer-review-guidelines make?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/open_outlook.php rake in every month?
- What's the income generated by https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/browse_hot_topics.php each month?
- Learn about the earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/podcasts
- Profit of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/blog
- How much cash flow does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/bulk_reprints.php have monthly?
- What's the financial gain of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/submit_step_1.php?
- What is the monthly revenue of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#?
- Find out how much https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/contact earns monthly
- What are the earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/sustainability.php?
- How much revenue does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/press-releases bring in?
- What's the financial outcome of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/why-publish-with-dove-press/testimonials?
- What's the profit of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/why-publish-with-dove-press/favored-authors?
- How much revenue does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/permissions.php bring in?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/presubmission_check.php bring in each month?
- What's the financial outcome of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/login.php?
- What's the financial intake of http://www.dovepress.com.cn?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/index.php generate monthly?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/search_advance.php earn?
- What's the monthly money flow for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/editorial_policies.php?
- Profit of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/script_status.php
- How profitable is https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/register.php?
- How much profit does https://www.dovepress.com/about_dovepress.php generate?
- What's the revenue for https://www.dovepress.com/why-publish-with-dove-press/open-access/?
- Learn about the earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/fav_author.php
- How much money does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/oncotargets-and-therapy-journal generate?
- Discover the revenue of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/oncotargets-and-therapy-archive23-v850
- What's the financial outcome of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/qr.php?p=https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT?
- Income figures for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/mailto:?subject=Open Access article on Dove Medical Press&body=Check out this article: https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT
- Income figures for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/article_metric.php?article_id=21455
- What's the financial gain of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/get_permissions.php?a_id=21455?
- What's the financial gain of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/author_profile.php?id=480357?
- What are the total earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/author_profile.php?id=341652?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/public_profile.php?id=15291 make?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/article/download/21455 earn?
- What's the total monthly financial gain of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref1?
- How much revenue does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref2 bring in?
- Get to know what's the income of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref3
- What's the total monthly financial gain of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref4?
- What's the profit of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#F1?
- What's the financial intake of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref5?
- What is the monthly revenue of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref6?
- How much revenue does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref7 generate?
- How much revenue does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref8 generate?
- What are the earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref9?
- What's the revenue for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref12?
- Monthly income for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/article/fulltext_file/53164/aW1n/OTT-53164-F01.jpg
- Income figures for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref13
- Income figures for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref14
- How much income is https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref15 earning monthly?
- What's https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref16's gross income?
- How profitable is https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref17?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref18 rake in every month?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref19 rake in every month?
- https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref20's total income per month
- See how much https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref21 makes per month
- What's the financial outcome of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref22?
- What's the income generated by https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref23 each month?
- What is the earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref24?
- What are the earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref25?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#T1 pull in?
- What's the total monthly financial gain of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/article/fulltext_file/53164/aW1n/OTT-53164-T01.png?
- What are the total earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref26?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref30 generate monthly?
- Monthly income for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref31
- Discover the revenue of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref32
- Financial intake of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref33
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref35 gross monthly?
- How much income does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref36 have?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref39 net monthly?
- What's the financial intake of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref40?
- What's the income of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref37?
- What's the income of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref38?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref41 bring in each month?
- https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref42 income
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref43 gross monthly?
- How much revenue does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref44 generate?
- Find out how much https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref45 earns monthly
- What's the monthly income of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref46?
- What's the total monthly financial gain of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref47?
- How much money does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref48 make?
- Get to know https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref49's earnings
- What's the revenue for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref50?
- What are the earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref51?
- Check the income stats for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref52
- Discover the revenue of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref53
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref54 rake in every month?
- What's the total monthly financial gain of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref55?
- See how much https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref56 makes per month
- What's the financial gain of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref57?
- Financial intake of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref58
- How much revenue does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref59 bring in?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref60 gross monthly?
- Discover the revenue of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref61
- https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref62's total income per month
- What's https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref63's gross income?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref64 make?
- Learn how profitable https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref65 is on a monthly basis
- Find out how much https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#ref66 earns monthly
- What's the income generated by https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft1 each month?
- See how much https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft2 makes per month
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft3 pull in?
- What's the income generated by https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft4 each month?
- How much profit is https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft5 making per month?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft6 net monthly?
- Monthly income for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft7
- Monthly income for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft8
- How much income is https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft9 earning monthly?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft10 earn?
- Income figures for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft11
- https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft12 income
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft13 make?
- What's the revenue for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft14?
- How much income is https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft15 earning monthly?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft16 bring in each month?
- What's the total monthly financial gain of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft17?
- Income figures for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft18
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft19 rake in every month?
- Discover the revenue of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft20
- Learn about the earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft21
- What's the income generated by https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft22 each month?
- What's the revenue for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft23?
- How much money does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft24 make?
- What's the income of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft25?
- How much revenue does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft26 produce monthly?
- What's the income generated by https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft27 each month?
- How much profit does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft28 make?
- How much money does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft29 generate?
- Financial intake of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft30
- How much money does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft31 make?
- What are the total earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft32?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft33 earn?
- How profitable is https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft34?
- What's the financial gain of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft35?
- Profit of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft36
- What's the financial gain of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft37?
- How profitable is https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft38?
- How much money does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft39 generate?
- Monthly income for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft40
- What's the total monthly financial gain of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft41?
- What's the financial intake of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft42?
- How much income does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft43 have?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft44 pull in monthly?
- Profit of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft45
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft46 make?
- How much profit does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft47 generate?
- What's the profit of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft48?
- What's the monthly money flow for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft49?
- Learn about the earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft50
- How much revenue does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft51 bring in?
- Get to know https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft52's earnings
- What's the total monthly financial gain of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft53?
- Learn how profitable https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft54 is on a monthly basis
- What's the profit of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft55?
- How much cash flow does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft56 have monthly?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft57 earn?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft58 make?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft59 pull in?
- What's the financial gain of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft60?
- Monthly income for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft61
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft62 pull in?
- What's the monthly money flow for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft63?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft64 bring in each month?
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft65 make?
- What's the monthly income of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft66?
- https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#reft67's financial summary
- How much profit is https://www.dovepress.com/terms.php making per month?
- Get to know what's the income of https://creativecommons.org/licenses/by-nc/3.0/
- Income figures for https://www.informa.com/privacy-policy/
- How much does https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/partners.php pull in?
- What's the income generated by https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/terms.php each month?
- Income figures for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/cookies.php
- What is the earnings of https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/#page-top?
- What's the revenue for https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-fulltext-article-OTT/privacy.php?
- Monthly income for https://phplab.nz/
- Financial intake of https://www.adhesion.co.nz
Analytics and Tracking {📊}
- Google Analytics
- Google Tag Manager
- Google Universal Analytics
Libraries {📚}
- jQuery
Emails and Hosting {✉️}
Mail Servers:
- mx.zoho.eu
- mx2.zoho.eu
- mx3.zoho.eu
Name Servers:
- josh.ns.cloudflare.com
- zita.ns.cloudflare.com
CDN Services {📦}
- Com/cm/ef49a3f1-d8c1-47d6-88fc-50e41130631f/airgap